Additionally, studies by Kirpotin et al. indicate that targeted portions on the surface of anti-HER2 immunoliposomes significantly increase the capture rate of NPs in tumor cells expressing HER2 compared to non-targeted liposomes, achieving intracellular drug delivery [328]. Here, ERBB2 is linked to neoplasm.